There was a high adherence of physicians to evidence-based guidelines in our study; fifty-six percentage of the selected physicians had prescribed SGLT2 inhibitors and GLP-1 agonists while managing patients with T2DM, who either developed or were at high risk of developing CVDs. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.